Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2025 11:07 ET | Source: Spherix Global Insights

US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights

EXTON, PA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable...
October 02, 2025 13:02 ET | Source: Spherix Global Insights

Physicians Signal Cautious Enthusiasm for Gene Therapy Across Hematology, But Adoption Remains Selective

New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and...
October 02, 2025 09:11 ET | Source: Spherix Global Insights

As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches

EXTON, PA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product Launches, which...
September 26, 2025 11:08 ET | Source: Spherix Global Insights

Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices

EXTON, Pa., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced the latest quarterly update to its RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) service,...
September 25, 2025 11:53 ET | Source: Spherix Global Insights

AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

EXTON, PA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the...
August 28, 2025 12:12 ET | Source: Spherix Global Insights

Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights

Exton, Pennsylvania, Aug. 28, 2025 (GLOBE NEWSWIRE) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S....
August 28, 2025 10:13 ET | Source: Spherix Global Insights

Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights

EXTON, PA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH)...
August 26, 2025 09:58 ET | Source: Spherix Global Insights

Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds

EXTON, PA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to switch their advanced...
August 25, 2025 10:14 ET | Source: Spherix Global Insights

US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights

EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in...
August 21, 2025 09:12 ET | Source: Spherix Global Insights

Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights

EXTON, PA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection...